EUVIMEDEUVIMED entdecken
Open Access

Long‐term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS)

Kerri Becktell iD, Yan Chen, Yutaka Yasui, Rachel Phelan, Gregory T Armstrong iD, Michael Link, Kevin Oeffinger, Claire Snyder, Najat Daw, Brent Weil, Christopher Weldon iD, Eric J Chow und 1 weitere

Pediatric Blood & Cancer · 2024-10 · 71 (10)

DOI: 10.1002/pbc.31189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 15.07.2024. Verfasst von Kerri Becktell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Cancer Survivors, Bone Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, American Lebanese-Syrian Associated Charities, Cancer Center Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Treatment strategies for osteosarcoma evolving between 1970 and 1999 improved 5‐year survival and continue as standard of care today. This report evaluates the impact of these evolving therapies on long‐term health outcomes.

Methods

Five‐year survivors of childhood osteosarcoma in CCSS treated from 1970 to 1999 were evaluated for late (>5 years from diagnosis) mortality, chronic health conditions (CHCs), and health status using piecewise‐exponential and logistical models. Comparisons were made between survivors and siblings without cancer, and among survivors examining historical and current standard chemotherapies (e.g., methotrexate/doxorubicin/cisplatin [MAP] vs. others), specific chemotherapy agents and surgical approaches (amputation vs. limb salvage [LS]). Models were evaluated adjusting for attained age, sex, race, ethnicity, and age at diagnosis.

Results

A total of 1257 survivors of osteosarcoma were followed on average for 24.4 years. Twenty‐year all‐cause late mortality was 13.3% (95% confidence interval [CI]: 11.7%–14.9%) overall and 11.7% (95% CI: 6.9%–16.5%) for the subset treated with MAP plus LS. Survivors were at higher risk of CHCs (rate ratio [RR] 3.7, 95% CI: 3.2–4.3) than the sibling cohort, most notably having more serious cardiac, musculoskeletal, and hearing CHCs. Within the survivor cohort, the risk of severe CHCs was twice as high with MAP versus no chemotherapy (RR 2.1, 95% CI: 1.3–3.4). Compared with primary amputation, serious musculoskeletal CHCs were higher after LS (RR 6.6, 95% CI: 3.6–13.4), without discernable differences in health status.

Conclusion

Contemporary osteosarcoma therapy with MAP plus LS, while improving 5‐year disease‐free survival, continues to be associated with a high burden of late mortality, CHCs, and health status limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaCancer SurvivorsBone NeoplasmsHumansFemaleMaleChildAdolescentChild, PreschoolAdultYoung AdultFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsSurvival RateInfant

Stichwörter der Autor:innen

long‐term outcomeosteosarcomasurvivorship

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Medicine and Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Departments of Medicine, Oncology, and Health Policy & Management, Johns Hopkins Schools of Medicine and Public Health, Baltimore, Maryland, USA.
  • Department of Pediatrics, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Kerri Becktell, Gregory T Armstrong, Christopher Weldon

Förderung

  • NCI NIH HHS
  • American Lebanese-Syrian Associated Charities
  • Cancer Center Support
  • National Cancer Institute

Zitieren

APA

Becktell, K., Chen, Y., Yasui, Y., Phelan, R., Armstrong, G. T., Link, M., Oeffinger, K., Snyder, C., Daw, N., Weil, B., Weldon, C., Chow, E. J., & Schwartz, C. L. (2024). Long‐term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). Pediatric Blood & Cancer, 71(10). https://doi.org/10.1002/pbc.31189

Vancouver

Becktell K, Chen Y, Yasui Y, Phelan R, Armstrong GT, Link M, et al. Long‐term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). Pediatric Blood & Cancer. 2024;71(10). doi:10.1002/pbc.31189

BibTeX
@article{Becktell2024,
  author = {Becktell, Kerri and Chen, Yan and Yasui, Yutaka and Phelan, Rachel and Armstrong, Gregory T and Link, Michael and Oeffinger, Kevin and Snyder, Claire and Daw, Najat and Weil, Brent and Weldon, Christopher and Chow, Eric J and Schwartz, Cindy L},
  title = {Long‐term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS)},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {10},
  doi = {10.1002/pbc.31189}
}
Kostenlos starten →